BrainsWay Invests $6M in Neurolief Following FDA Approval of Proliv™ Rx for MDD
BWAY has more than doubled off its 52-week low of $3.92.
Summary
BrainsWay completed an additional $6 million strategic investment in Neurolief Ltd., triggered by FDA Premarket Approval for Neurolief's Proliv™ Rx system for Major Depressive Disorder, expanding BrainsWay's market reach.
Key Events · M&A and Partnerships · BWAY
-
Strategic Investment Completed
BrainsWay finalized an additional $6 million convertible loan to Neurolief Ltd., bringing total investment to $11 million.
-
FDA Approval Milestone Met
The investment was triggered by Neurolief receiving FDA Premarket Approval for its Proliv™ Rx system for Major Depressive Disorder.
-
Market Expansion & Synergy
BrainsWay's CEO highlighted that Proliv™ Rx has the potential to expand their total addressable market and complement their Deep TMS™ technology.
-
Commercial Progress
Neurolief has begun scaling commercial operations, including securing a pathway into the VA health system for Proliv™ Rx.
Analysis · BWAY · Industrial Applications And Services
This filing details BrainsWay's completion of a $6 million milestone-based convertible loan to Neurolief, following the FDA's Premarket Approval of Neurolief's Proliv™ Rx system for Major Depressive Disorder. This investment, representing over 1% of BrainsWay's market capitalization, is a significant strategic move. The FDA approval for Proliv™ Rx is a key regulatory achievement for Neurolief, validating its technology and opening new commercial pathways, including access to the VA health system. BrainsWay views this as an opportunity to expand its total addressable market and create synergies with its existing Deep TMS™ technology, potentially leading to a future acquisition given BrainsWay's call option. Investors should monitor Neurolief's commercial progress and any further updates on BrainsWay's potential acquisition of the company.
At the time of this filing, BWAY was trading at $13.86 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $560.4M. The 52-week trading range was $3.92 to $14.65. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.